Viral Vector Manufacturing Market Research Report Information By Workflow (Upstream Manufacturing and Downstream Manufacturing), By End User (Pharmaceutical and Biopharmaceutical Companies and Research Institutes) And By Region (North America, Europe, Asia-Pacific, And The Rest Of The World) –Market Forecast Till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Viral Vector Manufacturing Market, by Type

6.1 Introduction

6.2 Retroviral Vectors

6.2.1 Lentiviral Vectors

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2 Gamma-Retroviral Vectors

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Adenoviral Vectors

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Adeno-Associated Viral Vectors

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5 Other Viral Vectors

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Viral Vector Manufacturing Market, by Disease

7.1 Introduction

7.2 Cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Genetic Disorders

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Infectious Diseases

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Viral Vector Manufacturing Market, by Application

8.1 Introduction

8.2 Gene Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Vaccinology

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Viral Vector Manufacturing Market, By End-user

9.1 Introduction

9.2 Pharmaceutical and Biotechnology Companies

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3 Research Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 10. Global Viral Vector Manufacturing Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Sanofi

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Lonza

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Merck KGaA

12.4.1 Company Overview

12.4.2 Product Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 UNIQURE N.V.

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Oxford BioMedica

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Spark Therapeutics, Inc.

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 UniQure N.V.

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 FinVector Vision Therapies

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Brammer Bio

12.10.1 Overview

12.10.2 Product Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Cell and Gene Therapy Catapult

12.11.1 Overview

12.11.2 Product Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Cobra Biologics

12.12.1 Overview

12.12.2 Product Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.13 REGENXBIO Inc.

12.13.1 Overview

12.13.2 Product Overview

12.13.3 Financials

12.13.4 Key Developments

12.13.5 SWOT Analysis

12.14 Kaneka Eurogentec S.A.

12.14.1 Overview

12.14.2 Product Overview

12.14.3 Financials

12.14.4 Key Developments

12.14.5 SWOT Analysis

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Viral Vector Manufacturing Industry

Chapter 14. Appendix

LIST OF TABLES

Table 1 Global Viral Vector Manufacturing Market Synopsis, 2020-2027

Table 2 Global Viral Vector Manufacturing Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

Table 4 Global Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

Table 5 Global Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

Table 6 Global Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

Table 7 Global Viral Vector Manufacturing Market, by Region, 2020-2027(USD Million)

Table 8 North America: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

Table 9 North America: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

Table 10 North America: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

Table 11 North America: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

Table 12 North America: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

Table 13 US: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

Table 14 US: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

Table 15 US: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

Table 16 US: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

Table 17 US: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

Table 18 Canada: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

Table 19 Canada: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

Table 20 Canada: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

Table 21 Canada: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

Table 22 Canada: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

Table 23 South America: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

Table 24 South America: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

Table 25 South America: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

Table 26 South America: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

Table 27 South America: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

Table 28 Europe: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

Table 29 Europe: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

Table 30 Europe: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

Table 31 Europe: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

Table 32 Europe: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

Table 33 Western Europe: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

Table 34 Western Europe: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

Table 35 Western Europe: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

Table 36 Western Europe: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

Table 37 Western Europe: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

Table 38 Eastern Europe: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

Table 39 Eastern Europe: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

Table 40 Eastern Europe: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

Table 41 Eastern Europe: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

Table 42 Eastern Europe: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

Table 43 Asia-Pacific: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

Table 44 Asia-Pacific: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

Table 45 Asia-Pacific: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

Table 46 Asia-Pacific: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

Table 47 Asia-Pacific: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

Table 48 Middle East & Africa: Viral Vector Manufacturing Market, by Type, 2020-2027 (USD Million)

Table 49 Middle East & Africa: Viral Vector Manufacturing Market, by Disease, 2020-2027 (USD Million)

Table 50 Middle East & Africa: Viral Vector Manufacturing Market, by Application, 2020-2027 (USD Million)

Table 51 Middle East & Africa: Viral Vector Manufacturing Market, by End-User, 2020-2027 (USD Million)

Table 52 Middle East & Africa: Viral Vector Manufacturing Market, by Region, 2020-2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Viral Vector Manufacturing Market

Figure 3 Segmentation Market Dynamics for Global Viral Vector Manufacturing Market

Figure 4 Global Viral Vector Manufacturing Market Share, by Type, 2020 (%)

Figure 5 Global Viral Vector Manufacturing Market Share, by Disease, 2020 (%)

Figure 6 Global Viral Vector Manufacturing Market Share, by Application, 2020 (%)

Figure 7 Global Viral Vector Manufacturing Market Share, by End-User, 2020 (%)

Figure 8 Global Viral Vector Manufacturing Market Share, by Region, 2020 (%)

Figure 9 North America: Viral Vector Manufacturing Market Share, by Country, 2020 (%)

Figure 10 Europe: Viral Vector Manufacturing Market Share, by Country, 2020 (%)

Figure 11 Asia-Pacific: Viral Vector Manufacturing Market Share, by Country, 2020 (%)

Figure 12 Middle East & Africa: Viral Vector Manufacturing Market Share, by Country, 2020 (%)

Figure 13 Global Viral Vector Manufacturing Market: Company Share Analysis, 2020 (%)

Figure 14 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.: Key Financials

Figure 15 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.: Segmental Revenue

Figure 16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.: Geographical Revenue

Figure 17 Sanofi: Key Financials

Figure 18 Sanofi: Segmental Revenue

Figure 19 Sanofi: Geographical Revenue

Figure 20 Lonza: Key Financials

Figure 21 Lonza: Segmental Revenue

Figure 22 Lonza: Geographical Revenue

Figure 23 Merck KGaA: Key Financials

Figure 24 Merck KGaA: Segmental Revenue

Figure 25 Merck KGaA: Geographical Revenue

Figure 26 UNIQURE N.V.: Key Financials

Figure 27 UNIQURE N.V.: Segmental Revenue

Figure 28 UNIQURE N.V.: Geographical Revenue

Figure 29 Oxford BioMedica: Key Financials

Figure 30 Oxford BioMedica: Segmental Revenue

Figure 31 Oxford BioMedica: Geographical Revenue

Figure 32 Spark Therapeutics, Inc.: Key Financials

Figure 33 Spark Therapeutics, Inc.: Segmental Revenue

Figure 34 Spark Therapeutics, Inc.: Geographical Revenue

Figure 35 UniQure N.V.: Key Financials

Figure 36 UniQure N.V.: Segmental Revenue

Figure 37 UniQure N.V.: Geographical Revenue

Figure 38 FinVector Vision Therapies: Key Financials

Figure 39 FinVector Vision Therapies: Segmental Revenue

Figure 40 FinVector Vision Therapies: Geographical Revenue

Figure 41 Brammer Bio: Key Financials

Figure 42 Brammer Bio: Segmental Revenue

Figure 43 Brammer Bio: Geographical Revenue

Figure 44 Cell and Gene Therapy Catapult: Key Financials

Figure 45 Cell and Gene Therapy Catapult: Segmental Revenue

Figure 46 Cell and Gene Therapy Catapult: Geographical Revenue

Figure 47 Cobra Biologics: Key Financials

Figure 48 Cobra Biologics: Segmental Revenue

Figure 49 Cobra Biologics: Geographical Revenue

Figure 50 REGENXBIO Inc.: Key Financials

Figure 51 REGENXBIO Inc.: Segmental Revenue

Figure 52 REGENXBIO Inc.: Geographical Revenue

Figure 53 Kaneka Eurogentec S.A.: Key Financials

Figure 54 Kaneka Eurogentec S.A.: Segmental Revenue

Figure 55 Kaneka Eurogentec S.A.: Geographical Revenue